NEW YORK (GenomeWeb) – Enzo Biochem today said that PerkinElmer will pay the firm $7 million as part of a legal settlement reached between the firms last week.

The settlement ends a patent dispute dating back more than a decade. PerkinElmer was one of several defendants named by Enzo in a patent infringement suit initially filed in 2002 in the US District Court for the Southern District of New York. The case surrounded patents licensed to Enzo covering the labeling, hybridizing, and detection of nucleotides.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: human T cell editing with CRISPR, retrotransposons acting as insulators, and more.

The New York Times' George Johnson muses on cancer's roots in multicellularity.

The San Diego Union Tribune wonders whether Medicare is ready for personalized medicine.

Jun Wang, the chief executive of BGI, has stepped down.